{"id":763528,"title":"Summary: NACI supplemental statement on Recombinant influenza vaccines, CCDR 48(9) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-03","captureTimestamp":"2026-03-03T00:12:23.104000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-9-september-2022/summary-national-advisory-committee-immunization-naci-supplemental-statement-recombinant-influenza-vaccines.html","snippet":"National Advisory Committee on Immunization (NACI) supplemental statement on recombinant influenza vaccines Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 48-9, September 2022: Invasive Diseases Surveillance in Canada Date published:…","rawSnapshotUrl":"/api/snapshots/raw/763528","browseUrl":"https://replay.healtharchive.ca/job-7/20260303001223/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-9-september-2022/summary-national-advisory-committee-immunization-naci-supplemental-statement-recombinant-influenza-vaccines.html#ha_snapshot=763528","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}